<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01201746</url>
  </required_header>
  <id_info>
    <org_study_id>PU-D/314/Acad</org_study_id>
    <secondary_id>HEC-20-685/06</secondary_id>
    <nct_id>NCT01201746</nct_id>
  </id_info>
  <brief_title>Influence of Periodontal Treatment on Systemic Inflammatory Mediators</brief_title>
  <acronym>Perio-CHD</acronym>
  <official_title>Influence of Periodontal Treatment on Systemic Inflammatory Mediators:hsC-reactive Protein, Fibrinogen and White Blood Cells in CHD Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheikh Zayed Federal Postgraduate Medical Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Higher Education Commission (Pakistan)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sheikh Zayed Federal Postgraduate Medical Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Currently the research issue in establishing the role of periodontal disease (PD) in coronary&#xD;
      heart disease (CHD) risk is to define the pathways that lead to cause-effect relationship&#xD;
      between PD and CHD. There is no consensus on definition of a periodontal disease case or the&#xD;
      threshold level that may give clear indication for this relationship. Periodontal therapy has&#xD;
      been used in different studies with the hope that a change in periodontal disease status may&#xD;
      modify the factors associated with CHD risk. Many of these studies, on role of periodontal&#xD;
      therapy in the reduction of CHD associated risk-factors, were based on small study samples,&#xD;
      and very few studies were randomized controlled trials. So a need for large prospective&#xD;
      studies is warranted in literature.----------- A single-blind parallel-arm randomized&#xD;
      controlled clinical trial was designed to observe the influence of periodontal treatment on&#xD;
      serum inflammatory mediators of hsC-reactive protein, white blood cells and fibrinogen in CHD&#xD;
      patients.&#xD;
&#xD;
      Hypothesis: Periodontal therapy in CHD patients, by reducing periodontal inflammation, may&#xD;
      decrease the host systemic inflammatory burden associated with atherogenic processes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>high-sensitivity C-Reactive Protein (hsCRP)</measure>
    <time_frame>1-3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fibrinogen</measure>
    <time_frame>1-3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>White Blood Cells</measure>
    <time_frame>1-3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">317</enrollment>
  <condition>Periodontal Disease</condition>
  <condition>Coronary Heart Disease</condition>
  <arm_group>
    <arm_group_label>Periodontal Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Scaling Root planing and oral hygiene instructions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Delayed treatment</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Scaling Root planing and oral hygiene instructions</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Delayed treatment</intervention_name>
    <description>Scaling, Root Planing and oral hygiene instruction</description>
    <arm_group_label>Delayed treatment</arm_group_label>
    <other_name>Control group</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Periodontal therapy</intervention_name>
    <description>Scaling, root planning and oral hygiene instructions</description>
    <arm_group_label>Periodontal Therapy</arm_group_label>
    <other_name>Experimental group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        A. General/Medical&#xD;
&#xD;
          1. Any race/ethnic group&#xD;
&#xD;
          2. Aged &gt; 30 years&#xD;
&#xD;
          3. Male or female&#xD;
&#xD;
          4. CHD case (CHD angiographically confirmed)&#xD;
&#xD;
          5. CHD diagnosed &gt; 3 months prior to entry into study.&#xD;
&#xD;
          6. No acute or chronic systemic conditions (see exclusion criteria below)&#xD;
&#xD;
          7. No medications/medication history that can interfere with the study (see exclusion&#xD;
             criteria below)&#xD;
&#xD;
          8. Non-smoker (=Never smoker) or former smoker (=Does not smoke now and has not smoked at&#xD;
             all for a minimum of the last 12 consecutive months)&#xD;
&#xD;
          9. Able and willing to comply with study procedures&#xD;
&#xD;
         10. Able and willing to be available for the duration of the study&#xD;
&#xD;
         11. Able and willing to provide signed informed consent&#xD;
&#xD;
        B. Oral/Periodontal&#xD;
&#xD;
          1. Dentate with at least 14 natural teeth, excluding third molars, that can be evaluated&#xD;
             periodontally.&#xD;
&#xD;
          2. Baseline whole mouth BOP &gt; 20% of sites.&#xD;
&#xD;
          3. Periodontitis case; periodontitis case defined as subject having ≥ 4 teeth with ≥ 1&#xD;
             site with PPD ≥ 4 mm &amp; CAL ≥ 3 mm at same site&#xD;
&#xD;
          4. No mechanical periodontal therapy in the last 6 months.&#xD;
&#xD;
          5. No acute oral diseases (mucosal lesions), oral infections, need for immediate&#xD;
             dental/periodontal care (e.g., NUG).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        A. General/Medical&#xD;
&#xD;
          1. Age ≤ 30 years&#xD;
&#xD;
          2. Not fulfilling criteria of defined CHD case&#xD;
&#xD;
          3. Fulfilling criteria of defined CHD case, but diagnosed ≤ 3 months prior to start of&#xD;
             study&#xD;
&#xD;
          4. Current smoker&#xD;
&#xD;
          5. Former smoker who does not smoke but who has smoked ≥ 1 cigarette (or equivalent, in&#xD;
             form of water pipe, pipe, cigar) in the last 12 months.&#xD;
&#xD;
          6. Females pregnant or lactating&#xD;
&#xD;
          7. Systemic chronic conditions known to be associated with periodontitis or with changes&#xD;
             in systemic inflammation: Diabetes,Rheumatoid Arthritis, Rheumatic Fever, SLE,&#xD;
             Malignancy, Respiratory diseases, Renal diseases, Other (e.g., autoimmune diseases,&#xD;
             fungal infections, immunological deficiencies, etc.)&#xD;
&#xD;
          8. Systemic acute conditions known to affect systemic markers of inflammation: Acute&#xD;
             bacterial infection, Acute viral infection (common cold, influenza, sinusitis),&#xD;
             Orthopedic trauma, Surgery&#xD;
&#xD;
          9. Medications known to affect systemic inflammatory biomarkers: Statins, Systemic&#xD;
             steroids, Non-steroidal anti-inflammatory drugs, Immunosuppressants,&#xD;
&#xD;
         10. Medications potentially affecting systemic inflammatory markers, if therapy started&#xD;
             less than 3 months prior to study such as Hormone replacement therapy, Contraceptives&#xD;
&#xD;
         11. Systemic antibiotic therapy in the last 3 months&#xD;
&#xD;
         12. Unable or unwilling to comply with study procedures&#xD;
&#xD;
         13. Unable or unwilling to be available for the duration of the study&#xD;
&#xD;
         14. Unable or unwilling to provide signed informed consent&#xD;
&#xD;
        B. Oral/Periodontal&#xD;
&#xD;
          1. &lt;14 teeth that can be periodontally evaluated (excluding 3rd molars)&#xD;
&#xD;
          2. BOP ≤ 20% of sites&#xD;
&#xD;
          3. Not fulfilling criteria of defined periodontitis case&#xD;
&#xD;
          4. Having received any periodontal therapy within last 6 months&#xD;
&#xD;
          5. Topical/local antibiotic or anti-inflammatory therapy in last 6 months&#xD;
&#xD;
          6. Acute oral infections&#xD;
&#xD;
          7. Oral wounds, including recent (&lt; 2 months) extractions&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>31 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ayyaz A Khan, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Sheikh Zayed Federal Postgraduate Medical Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Syed Akhtar H Bokhari, MCPS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sheikh Zayed Federal Postgraduate Medical Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohammad Azhar, MRCP</last_name>
    <role>Study Chair</role>
    <affiliation>Punjab Institute of Cardiology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Punjab Institute of Cardiology</name>
      <address>
        <city>Lahore</city>
        <state>Punjab</state>
        <zip>54300</zip>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Pakistan</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <study_first_submitted>September 13, 2010</study_first_submitted>
  <study_first_submitted_qc>September 14, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2010</study_first_posted>
  <last_update_submitted>October 13, 2016</last_update_submitted>
  <last_update_submitted_qc>October 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sheikh Zayed Federal Postgraduate Medical Institute</investigator_affiliation>
    <investigator_full_name>Syed Akhtar Hussain Bokhari</investigator_full_name>
    <investigator_title>PhD Candidate</investigator_title>
  </responsible_party>
  <keyword>Non-surgical periodontal therapy</keyword>
  <keyword>Coronary heart disease (CHD)</keyword>
  <keyword>periodontal Disease</keyword>
  <keyword>hsCRP</keyword>
  <keyword>Fibrinogen</keyword>
  <keyword>WBCs</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Periodontal Diseases</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

